Skip to Main Content

Paper Details

Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216).
J Clin Oncol
15
2022
17,20-lyase, Metastatic Hormone-Sensitive Prostate Cancer, Orteronel, PSA, TAK-700, androgen, bicalutamide, metastatic hormone-sensitive prostate cancer, orteronel, patients, prostate-specific antigen
Author NameAffiliation
Neeraj AgarwalUniversity of Utah Huntsman Cancer Institute
Maha HussainNorthwestern University, Robert H. Lurie Comprehensive Cancer Center
Primo N LaraUC Davis Comprehensive Cancer Center
Channing J PallerJohns Hopkins University School of Medicine
Ian M Thompson
David I QuinnNorris Comprehensive Cancer Center
  • 1 - 6

Datasets

Release 1.2